Navigation Links
Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
Date:7/23/2012

CAMBRIDGE, Mass., July 23, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

Having completed enrollment of a 150-patient randomized Phase 2 study in advanced non-small cell lung cancer, Cerulean is beginning to capitalize on the breadth of the CRLX101 opportunity by expanding its development into additional tumor types with several studies conducted by leading investigators.  This newly opened trial is designed to evaluate the activity of CRLX101, a nanopharmaceutical that inhibits both topoisomerase 1 and hypoxia-inducible factor-1 alpha, in ovarian cancer patients whose disease has progressed following standard first-line platinum-based therapy.  Current approved second-line therapy for ovarian cancer includes use of the topoisomerase 1 inhibitor, topotecan, which has limitations.  The study is being conducted at the Massachusetts General Hospital and led by principal investigator Carolyn Krasner, M.D., in cooperation with the Dana Farber Cancer Institute, Brigham and Women's Hospital, and Beth Israel Deaconess Medical Center.  

"Not only do women with advanced stage ovarian cancer have limited treatment options, but they also suffer from many disease-related symptoms and treatment-related side effects," said Dr. Krasner.  "This study will enable us to evaluate the potential use of CRLX101 as a treatment option for those patients." 

"This trial is intended to build on our current clinical data and determine if CRLX101 can offer ovarian cancer patients a new treatment option," said Edward Garmey, M.D., chief medical officer of Cerulean.  "We are excited to partner with Dr. Krasner and to expand the development strategy of CRLX101 in an indication with such high unmet needs."

About CRLX101

CRLX101 is an investigational anti-cancer agent that is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha.  CRLX101 is a dynamically tumor-targeted nanopharmaceutical designed to concentrate in tumors, prolonging drug exposure at the site of action.  Significant anti-tumor activity has been observed across a wide range of cancers in animal models.  CRLX101 is currently in Phase 2 clinical development.  More information on CRLX101 clinical studies can be found at www.clinicaltrials.gov.

About Cerulean Pharma Inc.

Cerulean Pharma Inc. is a clinical-stage company specializing in the development of dynamically tumor-targeted nanopharmaceuticals.  Cerulean is applying its proprietary nanopharmaceutical platform to advance a new class of therapeutic agents to address significant unmet medical needs.  With an initial focus in oncology, the Company's technology platform can be applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs.  Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, and CVF, LLC.  Cerulean is located in Cambridge, Massachusetts.  For more information, please visit the Company's website at http://www.ceruleanrx.com.

Media Contacts:
Schwartz MSL
Benjamin Navon/Kathy Vigneault
cerulean@schwartzmsl.com
+1 781-684-0770


'/>"/>
SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria
2. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
3. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
4. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
5. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. China Health Resource Announces Go Global Initiative For New Product Introductions
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. PDI, Inc. Announces Client FDA Product Approval Related to Previously Disclosed Contract
9. Ampio Pharmaceuticals Announces Closing of Public Offering
10. Boston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting
11. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):